1740P Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial

H Yamashita,J Inokuchi,K Maruo,H Ushijima,H Nishiyama,Y Kobayashi,Y Nagumo,H Azuma,Y Kita,T Naiki,Masae Takemura ,T Osawa,H Ishikawa,Y Kageyama,T Kimura,T Tsuzuki,T Kawai,Y Sekino,B.J Mathis,K Hashimoto

doi:10.1016/j.annonc.2022.07.1818

Abstract

Radical cystectomy (RC) is standard care for patients with muscle invasive bladder cancer (BC) or highest-risk non-muscle invasive BC. However, optimal care for bladder preservation or intolerance to RC remains uncertain. Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor with synergistic antitumor activity along with radiation therapy (RT), is a promising treatment.

Full Text